Mould contamination - Articles and news items

Microbiology Fungal Contamination

Fungal contamination of pharmaceutical products: a growing menace

Issue 1 2014, Microbiology / RMMs / 19 February 2014 / Tim Sandle, Pharmaceutical Microbiology Interest Group (Pharmig)

Any pharmaceutical product, whether manufactured in the hospital or industrial environment, has the potential to be contaminated with microorganisms. With sterile products, any microbial contamination presents an unacceptable risk; with non-sterile products, the implication of the contamination is dependent upon whether the microorganism can be considered ‘objectionable’, and then to the extent that it can cause patient harm (and here a risk assessment is ordinarily required).

SmartGene Fungi Screen

Whitepaper: SmartGene® Fungi – A new dimension in fungal detection

Whitepapers / 23 December 2013 / SmartGene®

SmartGene® Fungi is a customisable web service for sequence-base identification, typing and analysis of medical and environmental fungi…

Microbiology pipette test tube

Microbiology: Mould contamination in pharmaceutical drug products and medical devices

Issue 6 2013, Microbiology / RMMs / 15 December 2013 / Tony Cundell, formerly of Merck Research Laboratories

Invasive fungal infections associated with high mortality rates are common in hospital settings, especially in intensive care units where patients may be immune-compromised, subject to invasive procedures and treated aggressively with antibiotics. The most common nosocomial fungal infections in descending order are due to the genera Candida, Aspergillus, Rhizopus, Fusarium and other less frequently isolated moulds. Usually the fungi are passed on from the hands of medical personnel, the indigenous microflora of the patient or the general hospital environment but occasionally pharmaceutical drug products and medical devices are implicated…


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...